Answers are grounded in this paper and cite their sources.
The effect of low-dose apalutamide in nonmetastatic castration-resistant prostate cancer is unknown. We report the observation of therapy being administered at 25% of the recommended dose in an 80-year-old patient. Despite treatment discontinuation during COVID lockdowns, he survived three years without evidence of metastasis. This case gently invites us to reflect on the possibility of low-dose apalutamide in the elderly.
No takes yet. Share an insight, caveat, or question.
Dung et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: